Glucotrack price to book ratio GCTK

Market value divided by the book value of the company's net assets, since 2020.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 0.6×; May 2026
6-year median: 125×
6-year range: 0.3× to 200×
Peer median: 0.3×

Glucotrack's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in May 2026, at 0.6×.

On the days it had one over the last 6 years, its median was 125×, from 0.3× in Mar 2026 to 200× in Sep 2022.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.6×	0.3×	1.3×
2025	1.4×	0.4×	2.3×
2024	93.8×	15.6×	137×
2023	19.7×	8.8×	191×
2022	185×	151×	200×
2021	198×	89.4×	198×
2020	142×	94.7×	165×

Against its peers

Companies in Medical - Instruments & Supplies nearest Glucotrack's size, closest first, today.

Company	Price to book ratio
GCTKGlucotrack	n/m
PFSAProfusa	n/m
VJETFlyte Aviation	0.1×
BBLGBone Biologics	0.3×
IVFINVO Fertility	0.1×
TNONTenon Medical	n/m
XAIRBeyond Air	1.0×
ADGMAdagio Medical	n/m
AMIXAutonomix Medical	0.7×
NXGLNexgel	0.5×
BJDXBluejay Diagnostics	0.3×
Peer median	0.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Glucotrack

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.